BACKGROUND: The aim of the study was to investigate paraoxonase-1 (PON1) and aryl esterase (ARE) activities in patients with nonalcoholic fatty liver disease (NAFLD). MATERIALS AND METHODS: This case-control study was done on 83 subjects with confirmed NAFLD (50 male, 33 female, age; 40.46±12.13 years) and 138 healthy individuals (75 male, 63 female; age; 40.94±14.50 years). PON1, salt-stimulated PON1 and ARE activities were determined using paraoxon and phenyl acetate as substrate, respectively. RESULTS: The levels of PON1 activities in NAFLD and healthy individuals were 90.83±63.65 IU/L and 79.41±68.14 IU/L, respectively. There was no significant differences regarding PON1 activity between NAFLD and healthy subjects (p=0.229). While, ARE activity was significantly higher in NAFLD (83.34±28.36 KU/L) than in normal subjects (64.06±27.49 KU/L) (p<0.001). CONCLUSIONS: Our results showed that PON1 activity is not a promising biomarker for the evaluation of NAFLD while arylesterase may have, but further studies in larger samples with different ethnic groups are required to validate our findings.
BACKGROUND: The aim of the study was to investigate paraoxonase-1 (PON1) and aryl esterase (ARE) activities in patients with nonalcoholic fatty liver disease (NAFLD). MATERIALS AND METHODS: This case-control study was done on 83 subjects with confirmed NAFLD (50 male, 33 female, age; 40.46±12.13 years) and 138 healthy individuals (75 male, 63 female; age; 40.94±14.50 years). PON1, salt-stimulated PON1 and ARE activities were determined using paraoxon andphenyl acetate as substrate, respectively. RESULTS: The levels of PON1 activities in NAFLD and healthy individuals were 90.83±63.65 IU/L and 79.41±68.14 IU/L, respectively. There was no significant differences regarding PON1 activity between NAFLD and healthy subjects (p=0.229). While, ARE activity was significantly higher in NAFLD (83.34±28.36 KU/L) than in normal subjects (64.06±27.49 KU/L) (p<0.001). CONCLUSIONS: Our results showed that PON1 activity is not a promising biomarker for the evaluation of NAFLD while arylesterase may have, but further studies in larger samples with different ethnic groups are required to validate our findings.
Authors: Eline H van den Berg; Eke G Gruppen; Richard W James; Stephan J L Bakker; Robin P F Dullaart Journal: J Lipid Res Date: 2018-11-19 Impact factor: 5.922
Authors: Askın Tas Hekimoglu; Gulten Toprak; Hasan Akkoc; Osman Evliyaoglu; Selver Ozekinci; Ilker Kelle Journal: Korean J Physiol Pharmacol Date: 2013-04-10 Impact factor: 2.016